Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greater

被引：0

作者：

Tambo, Yuichi ^{[1
]}

Sone, Takashi ^{[1
]}

Shibata, Kazuhiko ^{[2
]}

Nishi, Kouichi ^{[3
]}

Shirasaki, Hiroki ^{[4
]}

Yoneda, Taro ^{[5
]}

Araya, Tomoyuki ^{[6
]}

Kase, Kazumasa ^{[7
]}

Nishikawa, Shingo ^{[1
]}

Kimura, Hideharu ^{[1
]}

Kasahara, Kazuo ^{[1
]}

机构：

[1] Kanazawa Univ Hosp, Resp Med, Kanazawa, Ishikawa, Japan

[2] Kouseiren Takaoka Hosp, Dept Med Oncol, Takaoka, Toyama, Japan

[3] Ishikawa Prefectural Cent Hosp, Dept Resp Med, Kanazawa, Ishikawa, Japan

[4] Fukui Ken Saiseikai Hosp, Dept Resp Med, Fukui, Japan

[5] Komatsu Municipal Hosp, Dept Resp Med, Komatsu, Japan

[6] Natl Hosp Org Kanazawa Med Ctr, Dept Resp Med, Kanazawa, Ishikawa, Japan

[7] Keiju Med Ctr, Dept Internal Med, Nanao, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.626

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MO25-3

引用

页码：S313 / S313

页数：1

共 50 条

[1] Real-world time on treatment (rwToT) with first-line pembrolizumab monotherapy in PD-L1 TPS ≥50% advanced NSCLC: 3-year follow-up data
Velcheti, V.
Hu, X.
Li, Y.
Burke, T.
Piperdi, B.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S755 - S755
[2] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
Velcheti, Vamsidhar
Hu, Xiaohan
Li, Yeran
El-Osta, Hazem
Pietanza, M. Catherine
Burke, Thomas
CANCERS, 2022, 14 (04)
[3] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Cortellini, Alessio
Tiseo, Marcello
Banna, Giuseppe L.
Cappuzzo, Federico
Aerts, Joachim G. J., V
Barbieri, Fausto
Giusti, Raffaele
Bria, Emilio
Cortinovis, Diego
Grossi, Francesco
Migliorino, Maria R.
Galetta, Domenico
Passiglia, Francesco
Santini, Daniele
Berardi, Rossana
Morabito, Alessandro
Genova, Carlo
Mazzoni, Francesca
Di Noia, Vincenzo
Signorelli, Diego
Tuzi, Alessandro
Gelibter, Alain
Marchetti, Paolo
Macerelli, Marianna
Rastelli, Francesca
Chiari, Rita
Rocco, Danilo
Gori, Stefania
De Tursi, Michele
Mansueto, Giovanni
Zoratto, Federica
Santoni, Matteo
Tudini, Marianna
Rijavec, Erika
Filetti, Marco
Catino, Annamaria
Pizzutilo, Pamela
Sala, Luca
Citarella, Fabrizio
Marco, Russano
Torniai, Mariangela
Cantini, Luca
Targato, Giada
Sforza, Vincenzo
Nigro, Olga
Ferrara, Miriam G.
D'Argento, Ettore
Buti, Sebastiano
Bordi, Paola
Antonuzzo, Lorenzo
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (11) : 2209 - 2221
[4] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
Alessio Cortellini
Marcello Tiseo
Giuseppe L. Banna
Federico Cappuzzo
Joachim G. J. V. Aerts
Fausto Barbieri
Raffaele Giusti
Emilio Bria
Diego Cortinovis
Francesco Grossi
Maria R. Migliorino
Domenico Galetta
Francesco Passiglia
Daniele Santini
Rossana Berardi
Alessandro Morabito
Carlo Genova
Francesca Mazzoni
Vincenzo Di Noia
Diego Signorelli
Alessandro Tuzi
Alain Gelibter
Paolo Marchetti
Marianna Macerelli
Francesca Rastelli
Rita Chiari
Danilo Rocco
Stefania Gori
Michele De Tursi
Giovanni Mansueto
Federica Zoratto
Matteo Santoni
Marianna Tudini
Erika Rijavec
Marco Filetti
Annamaria Catino
Pamela Pizzutilo
Luca Sala
Fabrizio Citarella
Russano Marco
Mariangela Torniai
Luca Cantini
Giada Targato
Vincenzo Sforza
Olga Nigro
Miriam G. Ferrara
Ettore D’Argento
Sebastiano Buti
Paola Bordi
Lorenzo Antonuzzo
Cancer Immunology, Immunotherapy, 2020, 69 : 2209 - 2221
[5] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
Itani, H.
Nigi, A.
Iwamoto, K.
Ito, Y.
Tanigawa, M.
Kondo, S.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
[6] First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort
Amrane, K.
Geier, M.
Corre, R.
Leveiller, G.
Florence, G.
Lamy, R.
Bizec, J. L.
Goarant, E.
Robinet, G.
Ulrike, S.
Quere, G.
Bernier, C.
Descourt, R.
ANNALS OF ONCOLOGY, 2019, 30
[7] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
Wu, Y.
Zhang, L.
Fan, Y.
Zhou, J.
Zhang, L.
Zhou, Q.
Li, W.
Hu, C.
Chen, G.
Zhang, X.
Zhou, C.
Dang, T.
Penrod, J.
Kush, D.
Qin, Y.
Li, B.
Mok, T.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
[8] Phase III Trial of Pembrolizumab-Chemotherapy Versus Pembrolizumab in First-Line of Advanced NSCLC with PD-L1 ≥50%: PERSEE
Descourt, R.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1011 - S1011
[9] The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
Tamiya, M.
Tamiya, A.
Hosoya, K.
Taniguchi, Y.
Yokoyama, T.
Fukuda, Y.
Hirano, K.
Matsumoto, H.
Kominami, R.
Suzuki, H.
Hirashima, T.
Uchida, J.
Morita, M.
Kanazu, M.
Sawa, N.
Hara, S.
Kinoshita, Y.
Kumagai, T.
Fujimoto, D.
ANNALS OF ONCOLOGY, 2019, 30
[10] Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Piedra, A.
Recio, S. Martinez
Gonzalez, A. Hernandez
Bueno, M. T. Moran
Arriola, E.
Recuero-Borau, J.
Dols, M. Cobo
Gonzalez, P. Cordeiro
Martinez, J. Mosquera
Garcia-Campelo, M. R.
Blanco, A. Calles
Alvarez, R. M.
Garcia, M. Zapata
Casado, M. D. Isla
Perez, A. Callejo
Gomez, P. Iranzo
Joaquin, A. Barba
Sullivan, I. G.
Felip, E.
Majem, M.
ANNALS OF ONCOLOGY, 2023, 34

← 1 2 3 4 5 →